Good questions, welcome aboard. 1. Most telehealth services send a set concentration (usually 2.5mg/mL) and you adjust the injection volume. At 2.5mg/mL, your 0.25mg dose = 0.1mL (10 units on an insulin syringe). As you titrate up to 1mg, you'd draw 0.4mL. Some switch you to a higher concentration vial at higher doses to keep injection volumes manageable. 2. Quality difference: a licensed 503B pharmacy is compounding under FDA oversight with mandatory sterility testing. Research-grade peptides are manufactured for "research purposes only" — there's no regulatory body verifying sterility or endotoxin levels. The active ingredient may test identically on HPLC, but the sterility assurance is where the gap lies. Some research sources are excellent; others are questionable. COAs tell you about purity and potency, not sterility. 3. BAC water: $8-$15 for a 30mL vial from Amazon or medical supply stores. One 30mL vial will last you through multiple reconstitutions. Budget maybe $30/year for BAC water plus $15-$20 for insulin syringes (100-pack). It's a negligible add-on cost. So your 6-month budget at the starting dose through Hallandale: roughly $200-$400 total depending on how fast you titrate. Through a telehealth bundle: $1,200-$1,800. Through brand Wegovy without insurance: $8,000+.

One thing missing from the price comparison — the cost of third-party testing if you go the research route. Janoshik full panel (HPLC purity + content + sterility + endotoxin) runs about $120-$150 per sample. If you're testing every batch, that adds significantly to your per-vial cost. At $99/vial + $130 for testing, you're at $229 — more than the pharmacy route. The workaround is community-funded batch testing (see the testing initiative thread). If 10 people order from the same batch and one person sends for testing, you split the cost — $13/person. That's more realistic. But honestly, for the peace of mind? Just use a licensed pharmacy. The price gap has narrowed enough in 2026 that the risk calculus doesn't favor research-grade the way it did in 2024 when pharmacies were charging $350+/vial.

Pharmacist here, adding some professional context. The price compression you're seeing in compounded semaglutide is driven by competition — there are now over 100 compounding pharmacies actively making semaglutide, compared to maybe 20-30 in early 2024. A few things to watch for: - API sourcing: Ask where the pharmacy gets their semaglutide API (active pharmaceutical ingredient). Reputable pharmacies use FDA-registered suppliers and can provide a Certificate of Analysis for the raw material, not just the finished product. - Beyond-use dating: A vial labeled with a 180-day BUD should raise eyebrows. Aqueous semaglutide stability data generally supports 90 days max for multi-dose vials with preservative. - Concentration creep: Some pharmacies are now offering 10mg/mL or even 20mg/mL concentrations. Higher concentrations mean smaller injection volumes but also tighter accuracy requirements when drawing doses. A 1-unit error on a U-100 syringe at 20mg/mL = 0.2mg dosing error. At 2.5mg/mL, the same 1-unit error = 0.025mg. Something to consider. Price is important, but it shouldn't be the only factor. A $50 savings isn't worth it if the product is degraded or contaminated.

Excellent addition from PharmD_Lurker. I'll incorporate concentration and BUD data into next month's comparison. Summary for March 2026: if you have insurance that covers Wegovy/Ozempic, use it — even with a $75 copay it's the lowest-risk option. If you don't, Hallandale at $155/vial represents the best value from a 503B facility. Telehealth bundles are convenient but carry a premium for that convenience. Research-grade is cheapest but requires the most due diligence. I'll post the April comparison in ~4 weeks. DM me with any pricing updates you encounter.